Cambia® is an oral solution formulation of diclofenac potassium and is indicated for the treatment of acute migraine attacks with or without aura in adult patients. Cambia® is the only available, approved, prescription non-steroidal anti-inflammatory drug (“NSAID”) for the treatment of acute migraine attacks in Canada.
Bezalip® SR is a modified-release tablet that contains the active ingredient bezafibrate, which is a type of medicine known as a fibrate. Bezalip® SR is indicated as an adjunct to diet and other therapeutic measures for mixed hyperlipidemia. Hyperlipidemia is defined as the elevation of plasma cholesterol, triglycerides (TGs), or both, or a low high-density lipoprotein (HDL) level that contributes to the development of atherosclerosis.
Soriatane® (acitretin) is a type of medicine known as a retinoid. Retinoids have a structure similar to vitamin A and are involved in the normal growth of skin cells. Soriatane® is indicated for the treatment for severe psoriasis (includes erythrodermic and pustular types) and other disorders of keratinization. Due to the risk of severe birth defects, Soriatane® should not be used in patients of reproductive potential.
NeoVisc® is a 1.0% solution of a highly purified, linear high molecular weight sodium hyaluronate which is derived entirely from non-animal sources. NeoVisc® is used to improve joint mobility and reduce joint pain.
Uracyst® is a fluid that is instilled into the bladder. It contains Sterile Sodium Chondroitin Sulfate Solution, 2.0%, and is effective in reducing the symptoms of painful bladder syndrome/interstitial cystitis.
Collatamp G® is a fully resorbable, gentamicin-impregnated collagen “sponge” for surgical implant that can be easily implanted during orthopedic, abdominal, cardiac, plastic or vascular surgery that can reduce the risk of surgical site infections.